Mitral regurgitation surgery overview: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Mitral regurgitation surgery}} {{CMG}}; '''Associate Editor-In-Chief:''' Mohammed A. Sbeih, M.D. [mailto:msbeih@perfuse.org] ==Overview== [[Mitral va...")
 
m (Robot: Automated text replacement (-msbeih@perfuse.org +msbeih@wikidoc.org, -psingh@perfuse.org +psingh13579@gmail.com, -agovi@perfuse.org +agovi@wikidoc.org, -rgudetti@perfuse.org +ravitheja.g@gmail.com, -lbiller@perfuse.org +lbiller@wikidoc.org,...)
 
(5 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link=Mitral Regurgitation intern survival guide]]|| <br> || <br>
| [[Mitral Regurgitation intern survival guide|Intern <br> Survival  <br> Guide]]
|}
{{Mitral regurgitation surgery}}
{{Mitral regurgitation surgery}}


{{CMG}}; '''Associate Editor-In-Chief:''' [[User:Mohammed Sbeih|Mohammed A. Sbeih, M.D.]] [mailto:msbeih@perfuse.org]
{{CMG}}; '''Associate Editor-In-Chief:''' [[User:Mohammed Sbeih|Mohammed A. Sbeih, M.D.]] [mailto:msbeih@wikidoc.org]


==Overview==
==Overview==
Vasodilator theray with ACE inhibitors and hydralazine is the mainstay of therapy in patient with chronic compensated mitral regurgitation. Acute mitral regurgitation requires urgent [[mitral valve repair]] or [[mitral valve replacement]].  MV surgery is beneficial for patients with chronic severe MR and NYHA functional class II, III, or IV symptoms in the absence of severe LV dysfunction (severe LV dysfunction is defined as ejection fraction less than 0.30) and/or end-systolic dimension greater than 55 mm.  MV surgery is beneficial for asymptomatic patients with chronic severe MR and mild to moderate LV dysfunction, ejection fraction 0.30 to 0.60, and/or end-systolic dimension greater than or equal to 40 mm. MV repair is recommended over MV replacement in the majority of patients with severe chronic MR who require surgery, and patients should be referred to surgical centers experienced in MV repair.


[[Mitral valve]] surgery is a surgery that can either repair or replace the mitral valve in the heart.
==References==
It then closes, keeping blood from flowing backwards.
{{Reflist|2}}
Mitral valve surgery is indicated when the [[mitral regurgitation]] is severe or when the patient is symptomatic.
Decision between valve repair or valve replacement is made based on the type and severity of damage to [[mitral valve]].
 
In '''open surgery''', the surgeon makes a large cut in the sternum to reach the heart.
'''Minimally invasive''' mitral valve surgery is done through much smaller surgical cuts than the large cuts needed for open surgery.


[[Category:Cardiology]]
[[Category:Cardiology]]
Line 19: Line 21:
[[Category:Overview complete]]
[[Category:Overview complete]]
[[Category:Template complete]]
[[Category:Template complete]]
[[Category:For review]]
[[Category:Valvular heart disease]]
[[Category:Valvular heart disease]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 15:53, 2 November 2012



Intern
Survival
Guide

Mitral regurgitation surgery

Home

Overview

Indications

Treatment

Preoperative Evaluation

Procedure

Recovery

Outcomes & Prognosis

Complications

Videos

Mitral regurgitation surgery overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mitral regurgitation surgery overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mitral regurgitation surgery overview

CDC on Mitral regurgitation surgery overview

Mitral regurgitation surgery overview in the news

Blogs on Mitral regurgitation surgery overview

Directions to Hospitals Performing Mitral regurgitation surgery

Risk calculators and risk factors for Mitral regurgitation surgery overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohammed A. Sbeih, M.D. [2]

Overview

Vasodilator theray with ACE inhibitors and hydralazine is the mainstay of therapy in patient with chronic compensated mitral regurgitation. Acute mitral regurgitation requires urgent mitral valve repair or mitral valve replacement. MV surgery is beneficial for patients with chronic severe MR and NYHA functional class II, III, or IV symptoms in the absence of severe LV dysfunction (severe LV dysfunction is defined as ejection fraction less than 0.30) and/or end-systolic dimension greater than 55 mm. MV surgery is beneficial for asymptomatic patients with chronic severe MR and mild to moderate LV dysfunction, ejection fraction 0.30 to 0.60, and/or end-systolic dimension greater than or equal to 40 mm. MV repair is recommended over MV replacement in the majority of patients with severe chronic MR who require surgery, and patients should be referred to surgical centers experienced in MV repair.

References

Template:WH Template:WS